Member Info for Dibs61

In that case could you give me your email address please? It’s important. If you don’t wish to disclose we’ll have to figure out another way

PaulFG - I have sent you a private message

That’s a big jump on the offer! Perhaps we’ll say a big delayed trade pop up later.

Much better day today. Disappointing response yesterday to what was a very good presentation by GM.

Buys marked as sells on here is NOT a manipulation. It is simply an outcome of how the mid price is calculated.

OBD has a number of different MM’s and all of these MM’s will have their own bid and offer prices - which can vary greatly. So, for example, atm the bid on LSE shows as 32.1

This means the lowest bid by any of the MM’s is 32.1

Conversely the offer here is shown as 34.9. This means the highest offer price currently amongst all the MM’s is 34.9

What LSE does is take the exact mid point between the lowest bid and highest offer and that is the mid or current share price - regardless of the actual share price quoted above.

So it is easy to see how, if you purchased your shares through a MM with a much lower offer price, the price you actually pay could conceivably be below the LSE calculated MID price.

I hope this makes sense and clears this up.

There is NO manipulation!

HTH

Added a further 10,453 @ 33.73

People will be kicking themselves for not taking advantage of these prices in just a few months, perhaps weeks, time.

Even crazier is I tried to get another cheeky 5k seconds later and got quoted 34.09!

A rise in the offer of 1.2p in seconds….🤷‍♂️

Topped up again. Managed to catch a momentary dip and got this:

02-Nov-23 12:50:31 32.90 9,547 3,141

Crazy but thx SETS

GM ‘hopeful we can do all this without funding’

Dug - it was noticeable from the CIRT Test sales chart how sales picked up more rapidly once the insurance code had been received. I expect PSE sales to ramp up more quickly because there is already pent up demand from the ‘unprecedented’ interest shown earlier in the year.

Dug - it was noticeable from the CIRT Test sales chart how sales picked up more rapidly once the insurance code had been received. I expect PSE sales to ramp up more quickly because there is already pent up demand from the ‘unprecedented’ interest shown earlier in the year.

I don’t think there ‘has’ to be one. There may still be one but, if not, no matter, it will still be interesting to hear what GM has to say.

He will, at the very least, set out the next steps and give us a clearer picture of the coming year and what we can expect. One of the things I would like to see is a renewed exploration programme to expand this mammoth resource.

I have just listened again to Jon Burrows in the May 2023 HY Webinar. His words regarding the CIRT and PSE test sales and I quote:

“We have a perfect Storm here and I am very very happy to report this to you. And I cannot wait to be able to report to you next January where this is all going.”

Could he be any more bullish or positive about Episwitch Test sales?

When it is clear that test revenues are ramping up exponentially the market will have no choice but to substantially rerate this stock. And will Jon Burrows be able to resist the temptation to give an interim update between now and January?

My apologies for clogging up the board today with my posts. I’m researching and wanting to make a few hopefully useful contributions. One more important point on funding and placings.

This company are the most upfront and transparent set up I have ever seen on AIM. Many companies on this market are vague at best and downright misleading at worst. Compare this with the following information about funding and working capital provided in 1 Aug RNS:

Quote:

Working Capital

Working Capital

“The Directors are of the opinion, having made due and careful enquiry, that, taking into account the net proceeds of the Placing and the Subscription and the revenue and other operating income that the Company expects to generate over the period, the working capital available to the Company is sufficient for its requirements until at least the end of June 2024. In the absence of higher product or project revenue or grant award funding, it would be necessary for the Company to raise additional funds, most likely in Q2 of 2024.”

So there is your answer - crystal clear - they could not be more open and transparent.

IMO this should give investors putting their money in here significant confidence.

Dug - FWIW I think another placing in the short term is EXTREMELY unlikely given the last one was barely three months ago! As you say it would question the company’s credibility. I also disagree totally that recent price action suggests a placing. It does NOT. We are seeing a period of SP consolidation at a much higher level. Some order filling.

We are in a SP uptrend. That’s a technical fact. And there is NO placing coming.

Taken from 1Aug RNS:

‘ Data from the PROSTAGRAM NHS study, published in Cancers, a high-impact, peer-reviewed journal in February 2023, showed that PSE demonstrated compelling results of 93% positive predictive value, 95% negative predictive value and overall accuracy of 94%. The Company experienced an unprecedented level of interest in the test following the announcement of the publication of these results, both from doctors and in the mainstream media. In response, the Company has moved quickly to expedite development and commercial launch of the test.

Two big take aways from this excerpt:

The company actually surpassed market expectations by launching the PSE Test EARLIER than expected. How many times does any AIM company actually beat a proposed completion date for anything?

Answer : Extremely rarely

Second point is they ‘experienced an unprecedented level of interest in the test following the announcement of the publication of these results,’

What can we deduce from this? It means there is very likely going to be a lot of interest from the medical community following the launch of the test. It could mean the early take up of the test will be more rapid and larger than that experienced after the launch of CIRT Test.

In terms of CIRT news I found this line in the 1st August Placing RNS:

‘ The Company is currently in discussions with two UK-based private medical groups for the use of CiRT, including one at an advanced stage of negotiation.’

We now know the ‘advanced’ one was BUPA which we have now landed. I think we can safely expect the announcement of a second one given BUPA’s enthusiastic take up of Episwitch CIRT.

Same price pattern today. Very quiet just now. Last few days have seen a few larger buy orders being filled.

Just also keep in mind that news can drop at ANY time with this company. Historically they have released a sizeable number of intraday RNS’s. So no red dot at 7am does not necessarily mean no RNS that day.

And we have a lot of news to come.

That’s two trading days on the trot we have finished up going by the mid price at close between the bid and ask BUT an UT keeps us unchanged @ 34. This despite there not being a single trade at 34 practically all day lol

It seems perhaps we ARE being kept at the station!

Oldbut- ‘smart money’ lol you mean all 300k shares sold in total against the 320k bought today